Epidemiological Analysis of Psoriasis in China from 2020 to 2022

Psoriasis is a persistent inflammatory skin condition driven by an immune response and influenced by both genetic and environmental factors. The high likelihood of disease recurrence has been a major concern for many patients, while the concurrent presence of other conditions has significantly impacted their quality of life.

To improve early detection of and treatment for patients by studying the epidemiological characteristics of patients with psoriasis in China.

The Psoriasis Real-World Big Data Collection Platform was initiated by the National Skin and Immune Diseases Clinical Medical Research Center (Beijing First Hospital of Peking University) in August 2020. During the period from August 2020 to June 2022, a total of 1012 hospitals across the nation participated in data entry. This article presents an epidemiological feature analysis based on the real case questionnaire survey form collected over the past 2 years.

The prevalence of psoriasis is highest among young and middle-aged men, affecting largely the skin area. Factors such as smoking, obesity, and family history are likely to influence disease onset. In this study's data, the limbs and trunk were the most common sites for psoriasis onset, with cardiovascular disease being the most prevalent comorbidity. Topical corticosteroid creams are frequently used in treatment by Chinese patients, along with a notable proportion opting for oral Chinese medicine for systemic treatment. Secukinumab is the primary choice when utilizing biological agents.

The actual data of patients with psoriasis from 2020 to 2022 offer crucial insights into the disease progression among the Chinese psoriasis population in recent years. Through an analysis of patient characteristics and treatment modalities, it furnishes valuable guidance for the prevention, early detection, and management of psoriasis.